Hansa Biopharma participating at LSX Nordic Congress
Idag, 15:35
Hansa Biopharma participating at LSX Nordic Congress
Lund, Sweden, 18 May. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, be participating in a panel discussion titled “Scaling Success: Key Drivers for Growing Nordic Biotechs” at the LSX Nordic Congress, in Copenhagen, at 13:10 CEST on Tuesday 19 , 2026.
If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com.
Event: Panel Discussion at LSX Nordic Congress
Title: Scaling Success: Key Drivers for Growing Nordic Biotechs
Date, Time, and Place: Tuesday 19 May, 13:10 CET, Copenhagen, Denmark
Moderator: Søren Bregenholt, CEO at Alligator Biosciences
Speakers:
- Renée Aguiar-Lucander, CEO, Hansa Biopharma
- Hans Schambye, Chair / CEO, DANSK BIOTEK / BOOST Pharma
- Colleen Acosta, CEO & Co-Founder, Freya Biosciences
- Johanna Roostalu, Director, Human Health, Venture Creation, BII
--- ENDS ---
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
Ämnen i artikeln
Hansa Biopharma participating at LSX Nordic Congress
Idag, 15:35
Hansa Biopharma participating at LSX Nordic Congress
Lund, Sweden, 18 May. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, be participating in a panel discussion titled “Scaling Success: Key Drivers for Growing Nordic Biotechs” at the LSX Nordic Congress, in Copenhagen, at 13:10 CEST on Tuesday 19 , 2026.
If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com.
Event: Panel Discussion at LSX Nordic Congress
Title: Scaling Success: Key Drivers for Growing Nordic Biotechs
Date, Time, and Place: Tuesday 19 May, 13:10 CET, Copenhagen, Denmark
Moderator: Søren Bregenholt, CEO at Alligator Biosciences
Speakers:
- Renée Aguiar-Lucander, CEO, Hansa Biopharma
- Hans Schambye, Chair / CEO, DANSK BIOTEK / BOOST Pharma
- Colleen Acosta, CEO & Co-Founder, Freya Biosciences
- Johanna Roostalu, Director, Human Health, Venture Creation, BII
--- ENDS ---
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com
Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
Ämnen i artikeln
Analys
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
